(484i) Fe3O4 Incorporated Metal Organic Framework MIL-100(Fe) As a Drug Carrier | AIChE

(484i) Fe3O4 Incorporated Metal Organic Framework MIL-100(Fe) As a Drug Carrier

Authors 

Bhattacharjee, A. - Presenter, Indian Institute of Technology Guwahati
Gumma, S., Cleveland State University

Fe3O4
promoted metal organic framework MIL-100(Fe): Can be a promising candidate as a
drug carrier

Abhik Bhattacharjee and Sasidhar Gumma

Department of Chemical Engineering, Indian Institute
of Technology Guwahati

Email: s.gumma@iitg.ernet.in

In this study, porous metal
organic framework (MOF) MIL-100(Fe) and magnetic nanoparticle MOF composites
i.e. Fe3O4@MIL-100 were investigated as drug delivery
vehicles for anticancer drug doxorubicin hydrochloride. Magnetite
is an inorganic metal oxide was chosen for its nontoxicity and high magnetic
saturation. MIL-100 (Fe) was synthesized by solvothermal route at about 150 °C from
its organic linker like trimesic acid (BTC). Magnetite were synthesized
according to standard procedures in literature to yield magnetic nanoparticles
(MNPs) of about 10-30 nm. A series of MNP and MOF composites i.e. Fe3O4@MIL-100(Fe)
were prepared by adding magnetite in different molar ratio in the raw precursor
of MIL-100 at temperature of 150 °C. All porous adsorbent samples were characterized
by X-ray diffraction, Nitrogen adsorption-desorption isotherm and Transmission
electron microscopy (TEM) methods. Doxorubicin hydrochloride (DOX), a well-known
anticancer drug for the treatment of various cancer syndromes like leukaemia,
lymphoma, and carcinoma was chosen as a model drug for current study. The drug was
loaded on to the MOF composite by equilibrating the aqueous DOX solution with
the porous MNP incorporated MOFs. For release study, “DOX” loaded carriers,
were dispersed in simulated phosphate-buffered saline (PBS) solution at a pH of
7.4 and incubated in a shaker at 37 °C in the dark. The sample was centrifuged
and the supernatants were collected for analysis at periodic time intervals. A
fresh PBS which is equal in volume to that of the sample withdrawn for analysis
is added to the contents of the incubation flask. The results indicate that the
drug loading capacities of the Fe3O4@MIL-100 for the
composites studied in this work are higher than both pure Fe3O4
and pure MIL-100. The release kinetics also indicate sustained and stable
release of “DOX” for more than ten days by incorporating MNPs into MOF
structure.

Table
1: Molar compositions and drug loading capacities of different carriers

Drug carriers

Molar ratio

Fe:BTC:Fe3O4

“DOX” Loading

(wt%)

Fe3O4

0:0:1

11.37

MIL-100

50:33:0

11.09

Fe3O4(50)@MIL-100

50:33:1

18.31

Fe3O4(100)@MIL-100

50:33:2

18.45

Fe3O4(125)@MIL-100

50:33:2.5

19.69

Fe3O4(150)@MIL-100

50:33:3

19.00

Fe3O4(200)@MIL-100

50:33:4

15.14

Fe3O4(400)@MIL-100

50:33:9

13.81

 

 

      
                   

Fig. 1:  TEM micrograph
of Fe3O4@MIL-100 and  “DOX” release study on different carriers

References:

1.
R. Massart, IEEE Trans.Magn., (1981), 17,1247.

2.
P. Horcajada et.al. Nature, (2010), 9, 172.

Topics